Malaria as a Risk Factor for COVID-19 in Western Kenya and Burkina Faso

PHASE3CompletedINTERVENTIONAL
Enrollment

143

Participants

Timeline

Start Date

January 8, 2021

Primary Completion Date

November 1, 2022

Study Completion Date

February 20, 2024

Conditions
Covid-19Malaria
Interventions
DRUG

Artemether-lumefantrine (AL)

Current first line treatment of malaria. Dose: Bodyweight (kg) Dose (mg) of artemether + lumefantrine given twice daily for 3 days (total, six doses) 5 to \< 15 20 + 120 15 to \< 25 40 + 240 25 to \< 35 60 + 360 \>=35 80 + 480; Twice daily for 3 days (total, six doses)

DRUG

Pyronaridine-artesunate (PA)

Antimalarial; Dose: Body weight (kg) Dose (mg) of pyronaridine + aresunate given once daily for 3 days (total, three doses) 5 to \< 8 60 + 20 8 to \<15 120 + 40 15 to \<20 180 + 60 20 to \<24 kg 180 + 60 24 to \<45 360 + 120 45 to \<65 540 + 180 \>=65 720 + 240; Once-daily for 3 days (total, three doses).

Trial Locations (2)

40100

Kisumu County Referral Hospital, Kisumu

06BP10248

Ouagadougou Hospitals, Ouagadougou

Sponsors
All Listed Sponsors
collaborator

London School of Hygiene and Tropical Medicine

OTHER

collaborator

Kenya Medical Research Institute

OTHER

collaborator

Groupe de Recherche Action en Sante

OTHER

collaborator

Centres for Disease Control and Prevention, Kenya.

OTHER

collaborator

Bill and Melinda Gates Foundation

OTHER

collaborator

Centers for Disease Control and Prevention

FED

lead

Liverpool School of Tropical Medicine

OTHER